Showing results (201-210 of 268) with videos related to
Sort By:
Pageof 27
AIDS (London, England)|March 9, 2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenJ L Casado, K Hertogs, L Ruiz, et al.Revista Clinica Espanola|June 1, 1990
[Visceral leishmaniasis in Alicante. Analysis of 21 cases]J Portilla Sogorb, J C Rosas Gómez de Salazar, J A Casellas Valde, et al.HIV Medicine|March 23, 2012
Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected menL Darwich, M P Cañadas, S Videla, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2000
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic responseR Paredes, T Puig, A Arnó, et al.AIDS (London, England)|April 20, 1999
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissueL Ruiz, J van Lunzen, A Arno, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2000
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIVF Puig-Basagoiti, M Cabana, M Guilera, et al.Revista Espanola De Sanidad Penitenciaria|July 12, 2013
[The progression of liver fibrosis in prison inmates co-infected by HIV and HCV who started on boosted protease inhibitor therapy]P Saiz de la Hoya Zamácola, C Alía Alía, A Marco, et al.Antiviral Research|June 16, 2000
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressureM Giménez-Barcons, A Sánchez-Fueyo, S Ampurdanés, et al.Journal of Dental Research|July 20, 2021
Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In VitroJ Muñoz-Basagoiti, D Perez-Zsolt, R León, et al.HIV Medicine|April 6, 2005
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulationsM Johnson, L Nieto-Cisneros, A Horban, et al.Pageof 27